1：Experimental Design and Method Selection:

Rational design of multifunctional pluronic P85/F127 nanoparticles (m-NPs) incorporating biotin for targeting and rhodamine-B for theranostic purposes. Methods include synthesis of functionalized polymers, nanoparticle preparation via thin-film hydration, characterization of physicochemical properties, stability studies, in vitro cell uptake and cytotoxicity assays, and cell cycle analysis.

2：Sample Selection and Data Sources:

Human glioblastoma cell lines (T98-G, U87-MG, U343) and normal fibroblast cell line (NIH-3T3) from ATCC. Drugs: verteporfin (VP) and temozolomide (TMZ).

3：List of Experimental Equipment and Materials:

Equipment includes Zetasizer Nano ZS for size and zeta potential, UV-Vis spectrophotometer (GE Ultrospec 7000), confocal microscope (Leica TCS SP8), flow cytometer (Guava easyCyte 8HT), SEM (Carl Zeiss Evo 50), AFM (Shimadzu SPM-9600), LUMiSizer for stability, and rotary evaporator (Buchi Rotavapor R-215). Materials include pluronic copolymers (F127, P85), biotin, rhodamine B, VP, TMZ, trehalose, and cell culture reagents.

4：5). Materials include pluronic copolymers (F127, P85), biotin, rhodamine B, VP, TMZ, trehalose, and cell culture reagents. Experimental Procedures and Operational Workflow:

4. Experimental Procedures and Operational Workflow: Synthesis of rhodaminated-P85 and biotinylated-F127, preparation of m-NPs by thin-film hydration, encapsulation efficiency measurement, stability tests in BSA and lyophilization, in vitro release studies, cell culture and uptake experiments, cytotoxicity assays with and without light irradiation, combined treatment studies, and cell cycle analysis via flow cytometry.

5：Data Analysis Methods:

Statistical analysis using GraphPad Prism with ANOVA and Tukey's test, synergy assessment via Chou-Talalay method using CompuSyn software, and data expressed as mean ± SD.